Concomitant use of mirtazapine and phenytoin: a drug–drug interaction study in healthy male subjects

Heading

Abstract

Objective. The objectives of this study were to assess the effect of mirtazapine on steady-state pharmacokinetics of phenytoin and vice versa and to assess tolerability and safety of the combined use of mirtazapine and phenytoin.

Methods. This was an open-label, randomised, parallel-groups, single-centre, multiple-dose pharmacokinetic study. Seventeen healthy, male subjects completed either treatment A [nine subjects: daily 200 mg phenytoin for 17 days plus mirtazapine (15 mg for 2 days continuing with 30 mg for 5 days) from day 11 to day 17] or treatment B [eight subjects: mirtazapine, daily 15 mg for 2 days continuing with 30 mg for 15 days plus phenytoin 200 mg from day 8 to day 17]. Serial blood samples were taken for kinetic profiling on the 10th and 17th days of treatment A and on the 7th and 17th days of treatment B. Induction of CYP 3A by phenytoin was evaluated by measuring the ratio of 6β-hydroxycortisol over cortisol on the 1st, 7th and 17th days of treatment B.

Results. Co-administration of mirtazapine had no effect on the steady-state pharmacokinetics of phenytoin, i.e. the area under the plasma concentration–time curve (AUC)_0–24 and peak plasma concentration (C_max) remained unchanged. The addition of phenytoin to an existing daily administration of mirtazapine resulted in a mean (±SD) decrease of the AUC_0–24 from 576±104 ng h/ml to 305±81.6 ng h/ml and a mean decrease of C_max from 69.7±17.5 ng/ml to 46.9±10.9 ng/ml. Induction of CYP 3A by phenytoin is confirmed by the significantly (P=0.001) increased 6β-hydroxycortisol/cortisol ratio from 1.74±1.00 to 2.74±1.64.

Conclusion. Co-administration of mirtazapine did not alter the steady-state pharmacokinetics of phenytoin. The addition of phenytoin to an existing daily administration of mirtazapine results in a decrease of the plasma concentrations of mirtazapine by 46% on average, most likely due to induction of CYP 3A3/4.